Trending...
- Making Time for Mythic Adventure - 175
- Long Beach: City Recaps Preparedness and Response Efforts on Peninsula Following Hurricane Marie Impacts - 119
- 'Nightmare' Star Mckenna Bridger Talks Psychological Thriller, Two-Part Shoot And Taking On Violet Adams - 113
SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $120 million Series C financing.
The financing was co-led by NEA, Abingworth, and Forge Life Science Partners with participation from other new investors Avego, PFM Health Sciences, and The Eleven Fund, as well as the company's existing investors The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners (OUP), and Altitude Life Science Ventures.
Proceeds from the financing will be used to advance the company's pipeline of two first-in-class product candidates in several indications. This includes clinical proof-of-concept studies for EP262 (MRGPRX2 antagonist) in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CindU) and atopic dermatitis (AD) and for EP547 (MRGPRX4 antagonist) in cholestatic pruritus.
More on The Californer
Escient's initial focus is on a novel class of cell surface receptors called Mas-related G protein-coupled receptors, or MRGPRs. MRGPRs are chemosensory receptors expressed on sensory neurons and immune cells, which reside in close proximity to one another in key barrier tissues such as the skin, airways and gastrointestinal tract. MRGPRs mediate the neuro-immune overactivation that is a hallmark of numerous chronic disorders, including many allergic, inflammatory, auto-immune, pain and pruritic diseases.
"By specifically blocking the activation of MRGPRX2 and MRGPRX4 with small molecule antagonists, we aim to develop effective oral medications with novel mechanisms of action for serious neurosensory-inflammatory diseases without the serious side effects observed with other approaches," said Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals. "We are thrilled with the support from both existing and new investors, and this significant financing puts us in a great position to advance our pipeline to clinical proof-of-concept in multiple indications."
More on The Californer
About Escient Pharmaceuticals
Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. The company's pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus. Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.
Visit www.escientpharma.com to learn more.
Contacts
Aaron Mishel
Chief Financial Officer
Escient Pharmaceuticals, Inc.
info@escientpharma.com
The financing was co-led by NEA, Abingworth, and Forge Life Science Partners with participation from other new investors Avego, PFM Health Sciences, and The Eleven Fund, as well as the company's existing investors The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners (OUP), and Altitude Life Science Ventures.
Proceeds from the financing will be used to advance the company's pipeline of two first-in-class product candidates in several indications. This includes clinical proof-of-concept studies for EP262 (MRGPRX2 antagonist) in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CindU) and atopic dermatitis (AD) and for EP547 (MRGPRX4 antagonist) in cholestatic pruritus.
More on The Californer
- GridSignal Launches Free Diagnostic to Reveal Hidden Power Capacity in AI Data Centers
- Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
- California: Trump wants to send a check? Pay Americans back the $108 billion his Iran War cost them at the pump first
- Reboot Ridge Introduces a Different Kind of Men's Wellness Retreat in San Diego, CA
- Dolly Parton And Loretta Lynn Tribute "At Heaven's Country Gate" Passes 55,000 YouTube Views
Escient's initial focus is on a novel class of cell surface receptors called Mas-related G protein-coupled receptors, or MRGPRs. MRGPRs are chemosensory receptors expressed on sensory neurons and immune cells, which reside in close proximity to one another in key barrier tissues such as the skin, airways and gastrointestinal tract. MRGPRs mediate the neuro-immune overactivation that is a hallmark of numerous chronic disorders, including many allergic, inflammatory, auto-immune, pain and pruritic diseases.
"By specifically blocking the activation of MRGPRX2 and MRGPRX4 with small molecule antagonists, we aim to develop effective oral medications with novel mechanisms of action for serious neurosensory-inflammatory diseases without the serious side effects observed with other approaches," said Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals. "We are thrilled with the support from both existing and new investors, and this significant financing puts us in a great position to advance our pipeline to clinical proof-of-concept in multiple indications."
More on The Californer
- From The Good Life Show to The American Dream: Shaun Alston's Story Comes Full Circle
- California: Governor Newsom announces appointments 9.16.2026
- California: Governor Newsom cuts red tape to accelerate new zero-emissions ferry project in San Francisco Bay
- New Westside Night Market Launches in Long Beach on Sept. 18
- Simplicity IT Named Finalist in 2026 MSP Titans of the Industry Awards for Community Impact
About Escient Pharmaceuticals
Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. The company's pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus. Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.
Visit www.escientpharma.com to learn more.
Contacts
Aaron Mishel
Chief Financial Officer
Escient Pharmaceuticals, Inc.
info@escientpharma.com
Filed Under: Business
0 Comments
Latest on The Californer
- Mom Era, Still That Girl: Family Art Tees 25% Off
- Fashion vs. Fascism - Because Democracy Should Always Be In Style
- California: Governor Newsom proclaims Latino Heritage Month
- Long Beach Public Works to Host Community Meeting on Anaheim Street Corridor Improvement Project
- Attn: ALL BUSINESSES: Read this book about this Marketing Math and start using this math TODAY!
- For International Equal Pay Day:Tell your co-workers about a Song about Money called "Big Bucks"
- Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast
- Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
- Chili Crisp Goes Premium: Gustus Vitae Debuts 5 All-Natural Seasonings, Handmade in California
- Registration Closes October 18 for YMCA Adventure Guides in Simi Valley, Conejo Valley
- International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
- California honored for nation-leading efficiency and data-driven improvements in state services and programs
- Boston Industrial Solutions Introduces Personalized Printing Training
- Mariachi México Lindo Releases Debut Album "Soy de Mexico"
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
- California: Governor Newsom signs wildfire recovery package to strengthen protections and focus on rebuilding for survivors
- Retro-Bit Announces Legendary Shoot 'em Up R-Type DX as its First Game Boy Color Release
- Stockdale Capital Partners Launches Real Estate Credit Platform
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
- FOCUS Names Mark Phillips Senior Vice President of Business Development